EcallantideSpecialist prescription medicine
Ecallantide inhibits plasma kallikrein, an enzyme involved in the production of bradykinin. It has been developed for acute hereditary-angioedema attacks.
What is Ecallantide?
Ecallantide is a plasma-kallikrein inhibitor developed for acute attacks of hereditary angioedema. It addresses a bradykinin-related form of swelling.
How it works
By inhibiting kallikrein, it reduces an upstream step in bradykinin production. This differs from blocking the bradykinin receptor itself.
Effects studied
Acute hereditary-angioedema symptoms
The EDEMA programme assessed symptoms during attacks against a comparison group. These findings concern treating an episode, not curing the inherited disorder or preventing every future attack. 1
Evidence: Placebo-controlled acute-attack studies
What does the evidence show?
The archive includes a placebo-controlled hereditary-angioedema trial. The findings concern a defined disease mechanism, not swelling in general.
A different kind of swelling
Hereditary angioedema can produce painful swelling in the skin, abdomen or airway. Bradykinin is an important driver in relevant forms of the disease. This differs from many familiar allergic reactions, so the word “swelling” alone is not enough to choose a treatment.
Where ecallantide intervenes
Plasma kallikrein helps generate bradykinin. By inhibiting the enzyme, ecallantide acts upstream of the receptor where bradykinin produces its effects. Icatibant addresses a different step by blocking the receptor itself. Shared clinical context does not make the two medicines identical.
What the acute-attack trials measured
The EDEMA trial programme assessed symptoms during attacks, using structured measures and a comparison group. That is evidence about treating an acute episode in a selected population. It should not be presented as prevention of all future attacks or a cure for the inherited condition. 1
Why professional supervision is central
Ecallantide can provoke anaphylaxis, which can be difficult to distinguish from worsening angioedema. For that reason, product information specifies the setting in which treatment can be given. Airway involvement is an emergency regardless of the medicine being considered. This draft does not supply a self-injection protocol or infer local availability from an overseas label. 2
Safety & status
Anaphylaxis can occur and may resemble worsening angioedema, making professional supervision essential. Airway involvement remains an emergency. 2
Country and product status
This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.
Frequently asked questions
Is it the same as icatibant?
No. Ecallantide inhibits kallikrein; icatibant blocks the bradykinin B2 receptor.
Does it treat every kind of swelling?
No. Bradykinin-mediated angioedema differs from many allergic and other causes of swelling.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Ecallantide: paper 10.1056/NEJMoa0905079 Research reference · Retained archive reference; not independently checked for this draft.
- Ecallantide: www.drugs.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.